Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
Background: Arthralgia is a common and debilitating toxicity of aromatase inhibitors (AI) that leads to premature drug discontinuation. We sought to evaluate the clinical and genetic risk factors associated with AI-associated arthralgia (AIAA). Methods: We performed a cross-sectional study among pos...
Main Authors: | Sally A.D. Romero, H. Irene Su, Jaya Satagopan, Q. Susan Li, Christina M. Seluzicki, Annika Dries, Angela M. DeMichele, Jun J. Mao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | Breast |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977619305788 |
Similar Items
-
Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy
by: Gulabi Mese, et al.
Published: (2013-02-01) -
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
by: Tara Hyder, et al.
Published: (2021-07-01) -
Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial
by: Inmaculada Conejo, et al.
Published: (2018-06-01) -
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01) -
Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
by: Sara Tenti, et al.
Published: (2020-08-01)